Suppr超能文献

主要桦树花粉过敏原Bet v 1的高效表达与纯化

High-level expression and purification of the major birch pollen allergen, Bet v 1.

作者信息

Hoffmann-Sommergruber K, Susani M, Ferreira F, Jertschin P, Ahorn H, Steiner R, Kraft D, Scheiner O, Breiteneder H

机构信息

Institute of General and Experimental Pathology, University of Vienna, Austria.

出版信息

Protein Expr Purif. 1997 Feb;9(1):33-9. doi: 10.1006/prep.1996.0671.

Abstract

Bet v 1, the single major allergen from birch pollen, shares IgE epitopes with all major tree pollen allergens from closely related species such as alder, hazel, hornbeam, beech, and European chestnut. Because of high sequence homologies among these allergens and the well-studied cross-reactivities on B cell epitopes, Bet v 1 is a representative model protein which can be used for in vitro studies. The cDNA coding for Bet v 1, the single major allergen from birch pollen, was cloned into the T7-based Escherichia coli expression system pMW 175/BL21(DE3) and synthesized as a nonfusion protein. In contrast to other E. coli systems (e.g., pKK233-2/JM105), this system produces high levels of readily extractable proteins corresponding to 5-10% of E. coli total protein, the percentage varying with culture conditions. The overall yield was 8-10 mg of purified recombinant protein per liter of culture medium. The recombinant allergen was purified by several steps, including ion-exchange and hydrophobic interaction chromatography. The purified recombinant allergen showed identical immunological properties with the respective natural counterpart. The use of recombinant allergens of high purity is expected to result in more accurate diagnostic procedures, but possibly also in a superior immunotherapy of Type I allergic diseases when compared with methods using crude allergen extracts containing various amounts of allergen concentrations.

摘要

Bet v 1是桦树花粉中的主要单一过敏原,与桤木、榛子、鹅耳枥、山毛榉和欧洲栗等近缘物种的所有主要树花粉过敏原具有IgE表位。由于这些过敏原之间存在高度的序列同源性,且对B细胞表位的交叉反应性已有充分研究,Bet v 1是一种可用于体外研究的代表性模型蛋白。编码桦树花粉主要单一过敏原Bet v 1的cDNA被克隆到基于T7的大肠杆菌表达系统pMW 175/BL21(DE3)中,并合成为非融合蛋白。与其他大肠杆菌系统(如pKK233-2/JM105)不同,该系统能产生高水平的易于提取的蛋白,其含量相当于大肠杆菌总蛋白的5%-10%,该百分比随培养条件而变化。每升培养基的重组过敏原总产量为8-10毫克。重组过敏原通过离子交换和疏水相互作用色谱等几步进行纯化。纯化后的重组过敏原与相应的天然过敏原具有相同的免疫学特性。与使用含有不同过敏原浓度的粗过敏原提取物的方法相比,使用高纯度重组过敏原有望带来更准确的诊断程序,也可能带来更优的I型过敏性疾病免疫疗法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验